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Abstract
Background: To date, research on priority-setting for new vaccines has not adequately explored the influence of 
the global, national and sub-national levels of decision-making or contextual issues such as political pressure and 
stakeholder influence and power. Using Kapiriri and Martin’s conceptual framework, this paper evaluates priority setting 
for new vaccines in Uganda at national and sub-national levels, and considers how global priorities can influence country 
priorities. This study focuses on 2 specific vaccines, the human papilloma virus (HPV) vaccine and the pneumococcal 
conjugate vaccine (PCV). 
Methods: This was a qualitative study that involved reviewing relevant Ugandan policy documents and media reports, 
as well as 54 key informant interviews at the global level and national and sub-national levels in Uganda. Kapiriri and 
Martin’s conceptual framework was used to evaluate the prioritization process. 
Results: Priority setting for PCV and HPV was conducted by the Ministry of Health (MoH), which is considered to 
be a legitimate institution. While respondents described the priority setting process for PCV process as transparent, 
participatory, and guided by explicit relevant criteria and evidence, the prioritization of HPV was thought to have been 
less transparent and less participatory. Respondents reported that neither process was based on an explicit priority 
setting framework nor did it involve adequate representation from the districts (program implementers) or publicity. 
The priority setting process for both PCV and HPV was negatively affected by the larger political and economic context, 
which contributed to weak institutional capacity as well as power imbalances between development assistance partners 
and the MoH. 
Conclusion: Priority setting in Uganda would be improved by strengthening institutional capacity and leadership 
and ensuring a transparent and participatory processes in which key stakeholders such as program implementers 
(the districts) and beneficiaries (the public) are involved. Kapiriri and Martin’s framework has the potential to guide 
priority setting evaluation efforts, however, evaluation should be built into the priority setting process a priori such that 
information on priority setting is gathered throughout the implementation cycle.
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Background
Vaccines are considered to be cost-effective health 
interventions, and play an important role in reducing under 5 
mortality if high coverage is achieved.1 Building momentum 
from the Millennium Development Goals (MDGs), 
particularly those focusing on children, development 
assistance partners, such as the World Health Organization 
(WHO), United Nations International Children’s Emergency 
Fund (UNICEF), and Global Alliance for Vaccines and 
Immunization (GAVI) have become increasingly interested in 
and committed to facilitating the development of new vaccines 
and scaling up the implementation of existing vaccines. For 
example, in 2010, the Gates Foundation committed $10 
million to vaccine research and the development and delivery 
of vaccines to the world’s poorest populations.2 
Growing interest in vaccines as a useful health intervention 
has led to a “vaccine boom.” By the end of 2008, there were 
more than 120 vaccine related products developed – the 
highest in a century. However, not all vaccines that are 
developed are recommended for adoption. Since 2010, the 
WHO has recommended at least 6 new vaccines for adoption 
by low-income countries (LICs), these include pneumococcal 
conjugate (PCV), dengue, hepatitis A, influenza, rotavirus, 
and human papilloma virus (HPV) vaccines.2 Furthermore, 
there are about 25 vaccines in the research and development 
pipeline.1 These new vaccines, if adopted, have to compete 
for the meager public health resources within LICs, who are 
already responsible for the provision of at least 6 existing 
routine vaccines. Financial and human resources, as well 
as physical infrastructure, are necessary for the successful 
implementation of any vaccine program. The resource 
requirements for adopting new vaccines are greater than 
for existing vaccines. For instance, some new vaccines have 
protocols and cold chain requirements that are different from 
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the routine vaccines and require retraining health workers 
and re-equipping health units.3 Prioritizing between new 
vaccines, while at the same time sustaining the existing vaccine 
program, is a major challenge for governments and Ministries 
of Health in LICs. Vaccine prioritization should occur through 
a clear and explicit process, as decisions to select one vaccine 
may occur at the cost of not investing in another and have 
consequences for health equity and outcomes. 
Studies have described the decision-making processes involved 
in adopting new vaccines in LICs. For example, Burchett and 
colleagues conducted a study on the decision-making process 
for introducing vaccines in 12 LICs and identified 11 criteria 
that influence the adoption of new vaccines.4 Expanding on 
these issues, Mantel and Wang discuss the adoption of new 
vaccines in a commentary.5 While these studies provides 
insight into the prioritization of new vaccines, Burchett and 
colleagues identify a need for more detailed case studies that 
expand our understanding of the process. In particular, they 
note that more research is needed to explore larger contextual 
issues such as political pressure and stakeholder influence and 
power, and whether the implementation of vaccine priorities 
reflects official national-level objectives and processes.4 This 
information is needed to identify the most effective ways to 
improve decision-making, and ultimately, health outcomes. 
This paper provides an in-depth exploration of priority setting 
for new vaccines in Uganda. The national and sub-national 
decision-making dynamics in the Ugandan public health 
system are similar to those in other LICs, and thus, provide a 
basis for generalizations beyond the Ugandan context. Based 
on the critical role that donors play in the adoption of new 
vaccines,3 this paper also considers how global priorities can 
influence country priorities. This study evaluates priority 
setting for vaccines in Uganda using Kapiriri and Martin’s 
conceptual framework for evaluating priority setting.6 This 
analysis is based on two specific vaccines, the HPV vaccine 
and the PCV.
Methods
The Analytical Framework
Kapiriri and Martin’s framework was developed in 2010 and is 
based on the priority setting literature and Delphi interviews 
with researchers involved in health prioritization research 
in low- and middle-income countries (LMICs). In 2015, the 
framework was validated by researchers and policy-makers 
in both global and LMIC contexts (Forthcoming), making 
it particularly relevant for an examination of priority setting 
for new vaccines in Uganda. The framework is holistic since 
it addresses the potential roles played by the social, cultural, 
political and economic context, which cannot be overlooked 
when discussing priority setting in LMICs. 
Kapiriri and Martin’s framework identifies 23 major 
parameters for successful priority setting (see Table 1).6 Each 
parameter is organized according to whether they are (1) 
internal/external relative to the priority setting institution, 
and (2) immediate/delayed; whereby immediate measures are 
expected within a planning/fiscal/budget year and delayed 
measures are expected beyond 3 fiscal years. Each parameter 
is associated with objectively verifiable indicator(s) (OVI) 
and means of verification (MOV). These specify the evidence 
that will inform evaluators if an expected measure has been 
achieved. By being objectively verifiable, these indicators 
permit different people, using the same measuring process, to 
obtain the same results independently.7
Data Collection
This is a qualitative study involving a review of documents 
and key informant interviews. 
Data collection strategies were aligned with the MOV 
proposed in the framework, where possible.
Document Reviews
Policy documents and media reports were reviewed. Policy 
documents include the health sector strategic and investment 
plans (HSSIPs) and the Uganda National Expanded Program 
on Immunization’s (UNEPI’s) comprehensive multiyear plans 
for immunization (CMYPs) between 2000-2015.8-13 While 
the HSSIPs describe the country’s priorities for new vaccine 
adoption, the CMYPs show what is actually implemented.
Media reports on HPV and PCV published within the same 
period were also reviewed. 
Media reports provide details of the rationale for the priorities 
set, and the process of rolling out vaccines to the public. 
Implications for policy makers
• An increasing number of new vaccines on the market and limited resources will always necessitate policy-makers to make informed decisions 
about which vaccines to introduce first.
• Using the examples of the prioritization of human papilloma virus (HPV)  and the pneumococcal conjugate vaccine (PCV), Kapiriri and 
Martin’s framework was able to identify areas of good practice and areas that require  improvement. 
• There is a need to integrate real-time evaluation into the priority setting processes for new vaccines such that information is gathered throughout 
the implementation cycle rather than ex-ante.
Implications for the public
New vaccines have the potential to improve quality of life, especially for those living in low-income countries (LICs). However, the number of new 
vaccines that LICs can potentially adopt is often greater than what LICs and their development assistance partners can afford to introduce. For this 
reason, LICs need to follow a priority setting process when identifying which vaccines to introduce first. Recommendations to improve priority 
setting for new vaccines should be based on an understanding of how these decisions are currently made.
This study evaluates the decision-making processes that led to the introduction of two new vaccines – PCV and HPV – from the global level to the 
point of delivery in Uganda. While the decision-making process was appropriate in some areas, it also fell short in others; for instance, there was a 
lack of publicity about the need to set priorities and the rationales behind the priorities that were identified. Transparency requires that decisions and 
their rationales  are available to the public.
Key Messages 
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Table 1. Parameters for Evaluating Priority Setting With Corresponding Means of Verification and Indicators
Immediate Parameters of Successful Priority Setting OVIs MOV
Efficiency of the priority-setting process Proportion of meeting time spent on priority setting, number of decisions made on time
Observations/minutes at meetings, annual budget documents, health 
system reports
Allocation of resources according to priorities
Degree of alignment of resource allocation and agreed upon priorities, times budget is re-allocated from less prioritized 
to high prioritized areas, stakeholder satisfaction with the decisions
Annual budget reports, evaluation documents
Stakeholder participation Number stakeholder participating, number of opportunities each stakeholder gets to express opinion Observations/minutes at meetings, media reports, special reports
Use of clear priority setting process/tool/method Documented priority setting process and/or use of priority setting framework Observation/minutes at meetings, media reports, special reports
Use of evidence
Number of times available data is resourced/number of studies commissioned/existing strategies to collect relevant 
data
Observations/minutes at meetings, media reports, special reports
Use of explicit relevant priority setting criteria Documented/articulated criteria Observations/minutes at meetings, media reports, special reports
Publicity of priorities and criteria Number of times decisions and rationales appear in public documents Media reports
Functional mechanisms for appealing the decisions Number of decisions appealed, number of decisions revised Observations/minutes at meetings, media reports, special reports
Functional mechanisms for enforcement Number of cases of failure to adhere to priority-setting process reported Observations/minutes at meetings, media reports, special reports
Fairer priority setting process a) relevance b) publicity 
c) revisions d) enforcement
Degree to which priority setting process aligns with 4 conditions of Accountability for reasonableness: relevance-
involvement of relevant stakeholders and relevant criteria, publicity of decisions, mechanisms for revisions and 
enforcement of priority setting process
Observations/minutes at meetings, media reports, special reports
Reflection of public values
Number and type of members from the general public represented, how they are selected, number of times they get 
to express their opinion, proportion of decisions reflecting public values, documented strategy to enlist public values, 
number of studies commissioned to elicit public values
Observations/minutes at meetings, study reports, meeting minutes and 
strategic plans
Increased public awareness of priority setting % of public aware of existing priority setting process Public awareness study 
Increased public confidence in and acceptance of 
decisions
Number of complaints from the public Reports, minutes from meetings, media reports
Delayed Parameters of Successful priority setting   
Increased stakeholder understanding, satisfaction and 
compliance with the priority setting process
Number of stakeholder attending meetings, number of complaints from stakeholder, % stakeholder that can articulate 
the concepts used in priority setting and appreciate the need for priority setting
Observations/minutes at meetings, special reports, stakeholder 
satisfaction survey, media reports, stakeholder interviews, evaluation 
reports
Decreased dissentions Number of complaints from stakeholder Meeting minutes, media reports
Decreased resource wastage Proportion of budget unused Budget documents, evaluation reports
Improved internal accountability/reduced corruption Number of publicized resource allocation decisions Evaluation reports, stakeholder interviews, media reports
Strengthening of the priority setting institution
Indicators relating to increased efficiency, use of data, quality of decisions and appropriate resource allocation, % 
stakeholders with the capacity to set priorities
Training reports, evaluation reports, budget documents
Impact on institutional goals and objectives % of institutional objectives met that are attributed to the priority setting process Evaluation reports, special studies
Impact on health policy and practice Changes in health policy to reflect identified priorities Policy documents
Achievement of health system goals
% Reduction in DALYs, % reduction of the gap between the lower and upper quintiles, % of poor populations spending 
more than 50% of their income on health care, % users who report satisfaction with the health care system
National budget allocation documents, human resources survey reports, 
Interviews with stakeholders
Improved financial and political accountability
Number of publicized financial resource allocation decisions, number of corruption instances reported, % of the public 
reporting satisfaction with the process
Reports, media reports, interviews with stakeholders
Increased investment in the health sector and 
strengthening of the health care system
Proportion increase in the health budget, proportion increase in the retention of health workers, % of the public 
reporting satisfaction with the health care system
Abbreviations: OVIs, objectively verifiable indicators; MOV, means of verification; DALY, disability-adjusted life year.
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Media reports also showcase public awareness of the priority 
setting process; the public is a key stakeholder in vaccine 
priority setting and new vaccine introduction requires 
intensive communication and social mobilization targeting 
communities to provide information about new vaccines.
Interviews
Interviews were conducted between 2013 and 2015. 
Respondents were identified from the 3 main levels of priority 
setting – the global, national and sub-national (district levels). 
Fifty-four interviews were conducted in total (see Table 2). 
Global level respondents provided context for understanding 
how global level priority setting impacts national level 
priority setting. National level respondents described the 
priority setting process within Uganda. Follow-up interviews 
with national actors provided information on which priorities 
were implemented and why. District level participants were 
critical since, according to the national health policy, district 
managers are responsible for policy implementation in 
Uganda. These participants provided insight into the enablers 
and barriers to policy implementation. 
Study Sample and Sampling Strategy
Purposive sampling was used, whereby only people deemed to 
be knowledgeable of, or involved in, new vaccine introduction 
were recruited. Respondents at the global level were identified 
through their organization’s web page. Within Uganda, the 
initial respondent was the officer in charge of the Expanded 
Program on Immunization (EPI); he identified subsequent 
respondents. Three districts were selected to reflect diverse 
settings, (ie, regional – North, Central and East, rural/urban, 
and new/old districts). 
The interviews were conducted by the principal investigator 
(LK) and trained Ugandan research assistants, using a 
pilot-tested interview guide. Global level interviews were 
conducted by telephone while the Ministry of Health (MoH) 
and district interviews were conducted face to face. Interviews 
lasted an average of 45 minutes and were audio recorded with 
permission from the respondents. 
Data Analysis
Interviews were transcribed verbatim and data were analyzed 
using Nvivo 10. Initially, 3 members of the research team 
independently read and coded two interviews, developing a 
list of codes. They then convened to discuss the code names 
and any discrepancies and to develop an agreed upon code 
list. Similar codes were grouped into categories and related 
categories linked to overarching themes. Further analysis 
involved using Kapiriri and Martin’s framework6 to assess the 
degree to which the described process met the parameters for 
successful priority setting (summarized in Table 1).6 
Results
Documented Priority Setting Processes for New Vaccines at 
the Global Level
World Health Organization
According to respondents, vaccines prioritized at the national 
level are chosen from a global menu of approved vaccines. 
This menu is created from a list of recommendations put 
forward by the WHO. Once a new vaccine product is 
developed and presented to the WHO, WHO seeks advice 
from its Strategic Advisory Group of Experts (SAGE). SAGE 
convenes advisory working groups with the relevant expertise 
to synthesize evidence and produce a position paper on new 
vaccines, which is publicized at the global, regional and 
national levels. SAGE provides recommendations to WHO, 
who present their recommendations to the World Health 
Assembly. This information filters down to the WHO in 
country and regional offices, who encourage countries to 
adopt the new vaccines. The criteria used by WHO for vaccine 
prioritization include: demand in the respective UN-supplied 
markets, WHO compliance needs with international health 
regulations, eradication, elimination or control initiatives and 
immunization program considerations, and finally, SAGE 
recommendations and the security/sustainability of supplies.14 
Respondents described how WHO plays an important role 
in the development of the new vaccine menu. For example, 
one individual argued that: “...there’s a lot of trust in the WHO 
team. By the time they heavily suggest an introduction of a 
vaccine it’s usually pretty much gospel truth…” [G_8]. 
Global Vaccine Alliance
While new vaccines may be recommended by WHO, the 
board of the GAVI independently approves the menu of 
vaccines that will be subsidized. WHO and GAVI priority 
vaccines are summarized in Table 3. GAVI undertakes a very 
systematic and rigorous process called a vaccine investment 
strategy every 2 to 3 years to determine which vaccines to 
support. Two of the most important criteria that GAVI uses to 
determine which vaccines to prioritize are cost-effectiveness 
and burden of disease. Once the menu has been finalized, 
GAVI calls for proposals from countries that are eligible for 
GAVI subsidization. Only LICs with a Gross National Product 
of less than $1580 are supported by GAVI.15
GAVI eligible countries must submit their proposals for 
vaccine introduction through country multi-year plans. 
After the submission of the proposal to GAVI, an assessment 
of the in-country capacity of the cold chain system and 
other logistics, known as an Effective Vaccine Management 
Assessment (EVMA) is conducted. This is followed by an 
Effective Vaccine Management Improvement Plan to improve 
the health system’s capacity to manage the new vaccine. This 
evidence is fed into the country’s GAVI proposals to indicate 
the country’s ability to sustain the introduction of the vaccine.
GAVI’s new vaccine introduction support consists of 
providing eligible countries with a substantially subsidized 
supply of the vaccine, as well as a one-time grant to assist with 
the initial expenses of vaccine introduction. The grant does 
not cover the full costs of new vaccine introduction, but rather 
works ‘‘to facilitate the timely and effective implementation of 
critical activities in the national vaccine introduction plan in 
Table 2. Study Participants by Level of Decision-Making
Level of Decision-Making Number of Respondents
District 27
MoH 19
Global level 8
Total 54
Abbreviation: MoH, Ministry of Health.
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advance of a new vaccine introduction and cover a share of 
the pre-introduction activities.”15
Multiple respondents described how GAVI affects the 
prioritization process at both the global and national levels, 
by influencing the choice of vaccines included on the new 
vaccine menu and through directly funding specific vaccines. 
“…the country is not allowed to get other vaccines partly 
because of the GAVI contract…” [G_8]. 
“...So yea if GAVI puts for us a menu of vaccines that they’re 
subsidizing it also kind of affects the priority setting process...” 
[G_4].
GAVI approves the menu of vaccines that can be subsidized 
in LICs. However, vaccines adopted are approved through 
extensive and participatory national level processes. These 
national level processes are described below. 
Documented Priority Setting Processes for New Vaccines at 
the National Level 
According to respondents, priority setting for new vaccines 
in Uganda is part of the national level priority setting process 
which involves the development of the HSSIPs, where 5-year 
national MoH priorities are identified by a broad range of 
stakeholders including government officers, development 
assistance partners, civil society organizations, and 
representatives from the districts. According to these reports, 
immunization and introduction of new vaccines have been 
consistently identified among the national priorities.8-10 The 
5-year plans specifically identify the new vaccines that should 
be introduced during the 5-year period. These decisions are 
guided by evidence presented by the medical officer in charge 
of the EPI, which has been derived from prior processes that 
are focused specifically on prioritization of new vaccines 
(described below). National level priorities are then presented 
to the Health Interagency Policy Advisory Committee 
(HIPAC), which gives the final approval and monitors vaccine 
implementation. 
Processes for New Vaccine Prioritization
The prioritization process for new vaccines involves 
different institutions and stakeholders namely: the Uganda 
National Academy of Science (UNAS), Uganda National 
Immunization Technical Advisory Group (UNITAG), or the 
Advisory Committee on Vaccines and Immunization (ACVI), 
the National EPI, the Maternal and Child Health Technical 
Working Group (TWG) and the HIPAC. The process is often 
triggered when the WHO and/or GAVI recommends a new 
vaccine. UNAS then takes the responsibility of electing a 
relevant advisory committee for the new vaccine, referred 
to as the NITAG or the ACVI. The composition and roles of 
these different institutions and committees are summarized 
in Table 4.
The UNAS has developed clear criteria for identifying 
members of the NITAG and explicit guidelines that the NITAG 
should use when evaluating the introduction of new vaccines. 
The NITAG collects and reviews evidence on the potential 
new vaccines and makes evidence-based recommendations 
to the UNAS. Based on these recommendations, the UNAS 
advises the TWG within the MoH, (chaired by the EPI 
manager). Once the TWG makes the decision to recommend 
the introduction of a new vaccine, the EPI manager develops a 
proposal and presents it to the senior management committee 
in the MoH; once approved this proposal is submitted to 
HIPAC. If Uganda were able to fund the introduction of the 
new vaccines, the next step would have been for the national 
medical stores to purchase the approved vaccines. However, 
since the country cannot afford the costs of new vaccines, 
they have to apply for funding from GAVI. Therefore, after 
the government structures have approved the introduction of 
a new vaccine – a critical condition for GAVI funding – the 
EPI manager includes those new vaccines in the proposal for 
GAVI funding. 
If a new vaccine is approved by GAVI, the country is funded 
to introduce the vaccine. However, before the funding is 
approved, GAVI conducts an in country EVMA, to establish 
the country’s readiness to introduce the new vaccine. Next, 
in country stakeholders utilize feedback from the GAVI 
secretariat to prepare an effective vaccine management 
improvement plan to ensure that the country is ready to 
implement the new vaccine. This may involve establishing 
in country surveillance to establish baseline indicators at 
introduction, cold chain preparation, waste management 
preparation, editing data management forms, health worker 
training, communication and community mobilisation. 
Once the recommendations have been implemented, GAVI 
releases the funds to facilitate the introduction of the new 
vaccine. Vaccines are then procured at the national level and 
delivered to the districts. While the districts are partly in 
charge of implementation, the EPI and the MoH are in charge 
of disease surveillance and reporting of adverse effects. The 
existing process has been described above. However, this 
process is not always followed, as was exemplified in the cases 
of introducing PCV and HPV. 
Table 3. Vaccines Recommended by WHO and Those Funded by GAVI
Priority Vaccines WHO GAVI
Cholera (oral) x x
DTwP-based combination containing IPV 
(DTwP-Hep B-Hib-IPV)
x -
Japanese encephalitis  - x
Dengue x -
Hepatitis A x -
HPV x x
Malaria x -
Measles-rubella x -
MMR x -
Pneumococcal conjugate x x
Polio (inactivated) [IPV] x -
Polio (bivalent live oral) (bOPV1,3) x -
Rotavirus x x
Typhoid conjugate x -
Yellow fever x x
Meningitis A - x
Pentavalent vaccine - x
Abbreviations: WHO, World Health Organization; GAVI, Global Alliance for 
Vaccines and Immunization; MMR, measles-mumps-rubella; HPV, Human 
Papilloma Virus; IPV, inactivated polio vaccine.
Source: http://www.who.int/immunization_standards/vaccine_quality/
pq_priorities/en/; http://www.Gavi.org/support/nvs/
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Priority Setting for New Vaccines in Uganda: The Cases of 
PCV and HPV
This section is organized according to the parameters 
of successful priority setting that could be evaluated 
(summarized in Table 5). It was not possible to evaluate 
some of the parameters namely: efficiency of the priority 
setting process, reflection of public values, increased public 
awareness of priority setting, increased public confidence in 
and acceptance of decisions, and decreased resource wastage. 
Allocation of Resources According to Priorities
According to this parameter, resource allocation should 
be based on the priorities that are identified. While the 
decision to introduce PCV was deemed appropriate by our 
respondents, several thought that the allocation of resources 
to HPV in 2005-2010 and 2010-2015 in the CMYPs was 
inappropriate since this did not match the new vaccines that 
were prioritized in the HSSIPs. For instance, in HSSIP III,8 the 
focus was on yellow fever and hepatitis B, yet resources were 
allocated to the introduction of HPV, in addition to hepatitis 
B and rotavirus.12 
Stakeholder Participation
This parameter relates to whether relevant stakeholders 
were involved in the priority setting process and were able to 
meaningfully contribute to the process. While the documents 
described a participatory process and explicit participation 
structures, our interviews revealed that not all the relevant 
stakeholders were actually involved in the process and that 
some stakeholders were involved in an inappropriate way. 
Stakeholders who were not adequately involved in the priority 
setting process include: MoH officers, district officers and the 
public. According to respondents, development assistance 
partners were involved in the priority setting process an 
inappropriate way. The participation of these stakeholders is 
discussed in detail below.
Development Assistance Partners
In participants’ discussions of priority setting for PCV 
and HPV, there was consistent reference to the role that 
development assistance partners played in the introduction 
of the new vaccines. In some cases, development assistance 
partners priorities seemed to trump considerations of explicit 
criteria. Participants discussed the way that development 
assistance partners’ influence led original vaccine priorities 
stated in the HSSIPs to be rearranged. For example, a 
policymaker from the MoH argued that the MoH’s decision to 
prioritize PCV was based on sound evidence; however, donor 
influence may have influenced the early introduction of HPV.
“…I’ll give an example, within the priorities that were set, 
what we [the MOH] had agreed was that a cost effective 
study was done and it was clear that if we introduced 
pneumococcus vaccine [first] it’s more cost effective. Now 
somebody comes up and gives a donation of HPV vaccine 
to the government…With that development, the priorities 
seem to change because now somebody has come with 
their agenda [to push for their] vaccine. And it looks like a 
tempting offer… So at the end of the day it’s like reversing 
[the HSSIP priorities] to start with HPV then PCV” [U_1].
There was a sense that development assistance partners’ 
adherence to a consultative priority setting process had 
decreased. Study participants who are members of development 
assistance partners argued that development assistance 
partners dominated forums for harmonizing partners, such 
as the Immunization Inter-Agency Coordinating Committee 
(IACC). According to one respondent, contrary to its 
intended role, the IACC had become “an opportunity for each 
partner to come with his influence” and to “push in a specific 
direction” and “the government has very little say in this type 
of forum” [G_7]. 
Ministry of Health Officers
While participants reported that the involvement of 
development assistance partners were uneven, they also 
alluded to 2 special categories of stakeholders – MoH 
officers and districts – who they thought were critical to 
the implementation of the new vaccine program, but were 
insufficiently involved in setting priorities for vaccines. There 
were sentiments that there was limited involvement of the 
MoH officers in the development of HSSIP III since at the 
Table 4. Documented Stakeholders and Institutions Involved in Priority Setting for New Vaccines in Uganda by Level of Decision-Making
Organization/Institution Level of Decision-Making Stakeholders Involved Roles
HIPAC, GAVI, UNICEF, WHO, USAID, 
JICA, PATH, AFENET Global, National Development assistance partners Funding, Technical and logistic support
MoH General National
Government officers (National and sub-
national)
Policy direction for prioritizing and 
monitoring new vaccines
MoH-EPI program and the Maternal 
Health Technical Working Group
National
Government officers, representatives from 
the civil society and the academia
Develops policy documents and 
recommendations to the MoH; and CMYPs 
for GAVI
UNAS and UNITAG National
Government officers, Academics, 
Pediatricians, Vaccinologists, Civil Society, 
Economists, Politicians, WHO health 
systems representative, technical advisors 
Technical support to provide objective and 
evidence based recommendations to the 
MoH for new vaccines
District Sub-national Local government officers
Implement routine and new vaccine 
regimens
Public
National and sub-national 
levels
Public 
Provide input on acceptability of new 
vaccines
Abbreviations: MoH, Ministry of Health; WHO, World Health Organization; UNICEF, United Nations International Children’s Emergency Fund; GAVI, Global 
Alliance for Vaccines and Immunization; USAID, United States Agency for International Development; HIPAC, Health Interagency Policy Advisory Committee; 
EPI, Expanded Program on Immunization; UNAS, Uganda National Academy of Science; UNITAG; Uganda National Immunization Technical Advisory Group; 
CMYPs, comprehensive multiyear plans for immunization; JICA, Japan International Co-operation Agency; AFENET, African Field Epidemiology Network.
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Table 5. Evaluating the Introduction of HPV and PCV Using the Parameters of Successful Priority Setting
Immediate Parameter of Successful Priority 
Setting
HPV PCV
Efficiency of the priority-setting process Impossible to determine Impossible to determine
Allocation of resources according to priorities
Although identified as a priority, HPV was not 
originally identified as a high priority in HSSIP II.
Identified as a priority in the HSSIP II. 
Stakeholder participation 
Participation of key stakeholders such as MoH staff 
and district officers limited
Same as HPV
Use of clear priority setting process/tool/
methods
No explicit framework or process used No explicit framework or process used 
Use of Evidence
Evidence from pilot project in 2 districts and several 
feasibility studies used
Evidence from sentinel surveillance reports and 
commissioned studies used
Use of explicit and relevant priority setting 
criteria
Burden of disease, equity used Burden of disease and cost-effectiveness used
Publicity of priorities and criteria
Media reports about benefits of vaccines, launching 
of vaccines, however public not informed of exact 
decision-making processes
Same as HPV
Functional mechanisms for appealing the 
decisions
None recorded Same as HPV
Functional mechanisms for enforcement None recorded Same as HPV
Fairer priority setting process (a) relevance (b) 
publicity (c) revisions (d) enforcement Less fair than for PCV Fairer than for HPV
Reflection of public values Impossible to determine Same as HPV
Increased public awareness of priority setting Impossible to determine Same as HPV
Increased public confidence in and 
acceptance of decisions
Impossible to determine Same as HPV
Delayed Parameter of Successful Priority 
Setting
Increased stakeholder understanding, 
satisfaction and compliance with the priority 
setting process
 
(a) Stakeholder understanding Limited understanding especially at district level Clearer since they followed due process of 
implementing HSSIP identified priorities
(b) Stakeholder satisfaction Dissatisfaction with the introduction of HPV when it 
was not part of the original plan
General satisfaction since PCV was part of the 
original HSSIP plan
(c) Stakeholder compliance Sense that compliance had deteriorated, especially 
that of donors
Same as HPV
Decreased dissentions
Other than media reports of complaints related 
to vaccines running out in districts, no complaints 
recorded
Same as HPV
Decreased resource wastage Impossible to determine Same as HPV
Improved internal accountability/reduced 
corruption
Institutional transparency low since criteria for 
prioritization thought to be irrelevant
Transparency better but still lacking because of lack 
of consultative process
Strengthening of the priority setting 
institution
See strengthening of the healthcare system See strengthening of the health care system
Impact on institutional goals and objectives See achievement of health system goals See achievement of health system goals
Impact on health policy and practice
No impact on health policy but impact on practice 
since changes in vaccine schedule
Same as HPV
Achievement of health system goals
Contributed to goal of reducing mortality and 
morbidity
Same as HPV
Improved financial and political accountability Financial accountability appears to be met for HPV
Respondents reported one instance where the 
resources where misappropriated but it was 
rectified. More stringent accountability mechanisms 
have been instituted
Increased investment in the health sector and 
strengthening of the health care system
Contextual issues weakened capacity to successfully 
engage in priority setting
Same as HPV
Abbreviations: HPV, Human Papilloma Virus; PCV, pneumococcal conjugate vaccine; HSSIP, Health Sector Strategic and Investment Plan; MoH, Ministry of 
Health.
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time, the MoH was only at 10% of its staffing levels. This plan 
was reportedly developed mainly through outsourcing. One 
Ugandan respondent working for a development assistance 
partner organization argued that while in the beginning 
stakeholders at all levels of government (including districts) 
participated in the priority setting process, with time, the 
process  became less consultative and transparent, with only a 
handful of actors from the MoH and development assistance 
partners driving the process. 
“…At the beginning the [priority setting] process was 
transparent and it was very consultative…We had excessive 
discussion with local leaders from the district, [and at 
the] national level, [we even had discussions with] line 
ministries, public service and finance…our partners both 
at the national level and sub national level…But over time 
the Ministry leadership has somehow weakened so the 
consultative [priority-setting] process has died down. Now 
it is prescriptive…the MoH comes up with priorities and 
they’re given to districts to implement... So the process has 
now been restricted to a few individuals [at the MoH] and 
the donors taking the upper hand” [U_ 20].
District Officers
Respondents reported a disconnect between national 
initiatives, such as the introduction of new vaccines, and 
processes within the districts. Participants argued that in 
many cases the districts are neither consulted during the 
priority setting process, nor made aware of the national 
vaccine priorities. This results in the districts failing to 
implement the vaccines since they have not put strategies 
in place to operationalize them. For example, 2 participants 
argued: 
“…Currently I think the link [between the national and 
district priority setting] is very poor” 
 [U_2].
“[The districts] didn’t have an annual work plan. So I don’t 
know what they’re implementing. So implementation is not 
being guided by priorities in the district” [U_10].
District-level respondents argued that they had not been 
given adequate opportunities to participate in priority setting 
discussions at the national level; they suggested that this was 
problematic since only individuals working at the district level 
could truly understand the specific needs of their population, 
and the feasibility of proposed interventions. 
“We need to set our own priorities according to the local 
context and local needs. We would be doing very well if 
we did...So the issue of decentralization is also needed to 
be looked at, it needs to be considered, and the district be 
empowered more so that they are able to implement their 
priorities” [D_3].
The Public
When setting priorities, it is important that the public, as the 
beneficiaries of the process, are involved. This can be achieved 
through having public representation on the priority setting 
committees or in institutions or by conducting public surveys 
where public opinions are considered during the priority 
setting process. The documents reviewed showed that there 
are efforts to include representatives from the public on 
various committees, such as the NITAG, that set priorities 
for new vaccines. The public is also represented through civil 
society organizations that participate in the HSSIP processes. 
This study was unable to assess actual participation of the 
public at these fora. In addition, the document review shows 
that, community level studies were conducted before the 
introduction of HPV and PCV. However their purpose was to 
assess the public’s readiness and their perceptions about the 
vaccines.16-18
Use of a Clear Priority Setting Process/Tool/Method
According to the framework, priority setting should involve 
the use of an explicit process, tool or method. The documents 
reviewed showed that Uganda’s MoH does not use an explicit 
method or framework for priority setting, although they 
have articulated a clear process. Despite the existence of 
a clear process, it is not always followed. For example, in 
2008, yellow fever and hepatitis B vaccines were identified 
as priorities in HSSIP II,9 while the CMYP11 identified and 
prioritized the introduction of HPV vaccine in 2008 and 
increased surveillance of hepatitis B and rotavirus in 2008 and 
2006 respectively. However, no mention was made of yellow 
fever vaccine. In HSSIP III,8 the focus was on Haemophilus 
influenzae type B, pneumococcus, yellow fever, hepatitis B 
and rotavirus vaccines, and there was no mention made of 
HPV. However, in the corresponding CMYP,12 the priorities 
were to complete the programmatic evaluation of HPV 
vaccination by 2010, to introduce PCV into the routine 
immunization schedule by 2010, and to vaccinate 90% of 
children with PCV3 by 2013. In addition, the CMYP aimed 
to introduce Rotavirus vaccine into the routine immunization 
schedule by 2013.12 
Use of Evidence
Pneumococcal Conjugate Vaccine 
According to Kapiriri and Martin’s framework,6 using 
evidence to guide priority setting can discourage the use of 
controversial criteria, such as politics, hence increasing the 
appropriateness of decision-making. The review of GAVI 
applications also showed that the MoH placed considerable 
emphasis on generating locally-relevant data to support the 
introduction of the PCV vaccine. For example, a sentinel 
disease surveillance and reporting system for pneumococcal 
disease was initiated in 2002, which generated evidence that 
supported the case for the introduction of PCV. Evidence on 
the high disease burden of invasive pneumococcal diseases 
such as meningitis and pneumonia (respectively 28/1000 
and 3212/1000 for children below 5 years), the anticipated 
benefits, especially for children, and the health system’s 
readiness, as demonstrated by the EVMA, all supported the 
introduction of PCV.13 In addition to this, several studies were 
conducted prior to the introduction of PCV, for example, a 
cost-benefit analysis study18 and another study exploring the 
role of the public.19
The evidence from the Ugandan surveillance system 
supported the selection of PCV-13, which addresses more 
strains of pneumococcus and is more compatible with 
the Ugandan context, in terms of cost, ease of handling, 
management, storage, and fit in the immunization schedule; 
however, excessive demand for PCV-13 at the global level led 
to the MoH being forced to choose PCV-10 instead of the 
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more locally appropriate PCV-13.
Human Papilloma Virus Vaccine
Several studies were conducted and published prior to the 
introduction of HPV vaccine in Uganda. Some of these 
studies examined opportunities and obstacles in delivering 
the vaccine17,20 formative research by PATH21 and research 
on delivery and readiness.16,22 However, it is not clear if these 
studies were conducted in preparation for the implementation 
of the HPV vaccine. They may have not influenced the initial 
prioritization of the vaccine.
Use of Explicit Relevant Priority Setting Criteria 
In order for priority setting to be fair, it should be based on 
relevant reasons or information such as epidemiological 
information, considerations of equity, or data on costs and 
effectiveness of interventions. Discussions with participants 
and the HSSIPs indicate that acceptable criteria, such as 
use of evidence, and considerations of equity, in addition to 
unacceptable criteria, such as political sentiment, and industry 
and donor priorities influenced the decision to prioritize the 
HPV and PCV vaccines.
Pneumococcal Conjugate Vaccine 
Our interviews with study participants and a review of 
documents reveals that considerations of equity, (since PCV 
focuses on children who are considered to be vulnerable), 
cost effectiveness, and burden of disease were critical in the 
MoH’s choice to introduce PCV. For example, one respondent 
explained that based on cost effectiveness, PCV was planned 
to be introduced ahead of vaccines such as HPV.
Human Papilloma Virus Vaccine
Unlike PCV, there is limited information on the criteria 
that facilitated the MoH’s prioritization of the HPV vaccine. 
Participants described how equity was an important criterion 
considered in the prioritization of HPV. According to one 
Ugandan policymaker, the HPV vaccine targets women, and 
its prioritization was a result of the importance of gender 
equity. He explained that the MoH’s prioritization of the HPV 
vaccine is a good example of the way in which equity as a 
criterion can trump other considerations such as evidence of 
burden of disease:
“I think HPV was likely taken on for equity reasons…Women 
felt they were being ignored…if we were to set priorities 
based on morbidity patterns [alone], I think HPV wouldn’t 
have appeared” [U_ 9].
Some participants identified criteria that they thought not to 
be relevant to prioritizing new vaccines. For example, global 
participants argued that HPV became a priority because 
pharmaceutical companies promoted the vaccine, while 
national respondents thought it was partly influenced by 
political sentiments. According to one participant, industries 
are more likely to promote the introduction of more profitable 
vaccines like HPV compared to vaccines for diseases such as 
measles: 
“…if there is a donor with a lot of money and he has a new 
product… they will find a way. We are challenged at this 
moment with the HPV…I think it’s a fantastic vaccine and 
every woman should have it…but industry is so interested 
in selling that and they’re not so interested in selling the 23 
cents for measles vaccine.…usually [it is] the governments or 
the research scientists pushing [their priorities] but now we 
have the industry actually who can make a profit out of these 
things pushing their priorities…” [G_8].
Some of the national-level participants argued that the 
government rushed to adopt the HPV vaccine, despite the 
fact that this decision was not necessarily a result of evidence 
or logistical considerations. As one researcher from Uganda 
explains, the influence of politics can offset priorities based 
on evidence, and can derail considerations of the impact of 
adopting a new vaccine on the health system:
“…But a lot of times what I’ve seen is it’s often a political 
decision. So there’s a difference between the technical and 
the political priorities. Of course for a politician the disease 
that they see more happens to be cancer so there was a big 
push [to prioritize the] HPV vaccine even before PCV and 
rotavirus vaccines. So that’s a big challenge. If tomorrow 
you told [the President] that there’s now a malaria vaccine 
that will be ready, you have to go buy this vaccine. Because 
immunization is one of the areas that are very important 
to him, [it will be done without consideration of] the 
technicalities of introducing that new vaccine, the cold 
chain requirements, how are they imported, is there enough 
money?” [U_13].
Publicity of Priorities and Criteria
Transparency is important to fair decision-making. The 
publicity condition requires that the decisions and the 
rationales and criteria on which they are based are available to 
the public. In Uganda, attempts to publicize decisions occur 
mainly through the print media. There were a couple of media 
reports on the introduction of the new vaccines, with varied 
content. For example, newspapers reported on the incidence 
of meningitis and cervical cancer, the government’s plans, with 
support from GAVI, to introduce PCV,23 and the HPV pilot 
implementation.21 Furthermore, there were media reports 
about the magnitude of the health problems being addressed 
and the need for the public to respond positively.24-26 The 
launches of vaccines in many districts (for example, the launch 
of PCV by the president) were also often highly publicized.23 
Other media reports were about the limitations of the new 
vaccine programs with some questioning the sustainability of 
the funding (given the prior misappropriation of funds), and 
history of vaccine stock outs.29-32 In some of the newspaper 
reports, the public reacted negatively to HPV. Although the 
decision to adopt both vaccines was disseminated to the 
public through popular media, these media reports did not 
inform the public of the process and rationale used to identify 
the vaccine priorities. 
Functional Mechanisms for Appealing and Revising the 
Decisions
According to this condition, there should be mechanisms for 
appealing the decisions and opportunities for revising the 
decisions, based on new evidence. This study did not identify 
any explicit appeals and revisions mechanisms. The only 
avenue for channeling complaints seems to be through the 
media (discussed above). 
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Functional Mechanisms for Enforcement
According to Kapiriri and Martin’s framework,6 there 
should be internal or external mechanisms to ensure a fair 
process. While the MoH does have structures that oversee 
the implementation of the new vaccines, there were no 
mechanisms that explicitly focused on assuring that the 4 
conditions of a fair process are met.
Fairer Priority Setting Processes
According to the framework, priority setting should 
be perceived as fair. A fair process meets the following 
conditions: relevance – ie, stakeholder participation, use of 
evidence, use of explicit relevant criteria – publicity, revisions 
and enforcement (see Table 4).33 From the above discussion it 
is clear that while there were attempts to meet the conditions 
of a fair process, none was fully met.
Increased Public Confidence in and Acceptance of Decisions 
As discussed above, newspaper reports suggested that the 
public reacted negatively to the introduction of the HPV 
vaccine. However, no explicit complaints or revisions to the 
decisions were documented or mentioned by respondents.
Increased Stakeholder Understanding, Satisfaction and 
Compliance With the Priority Setting Process and Decreased 
Dissentions
Stakeholders are key to the success of any priority setting 
process. Stakeholder involvement in the process or their 
exposure to the publicized information (discussed above) 
would facilitate their understanding of priority setting. Their 
involvement would also contribute to their satisfaction and 
compliance with the outcome of the process and would result 
in reduced dissentions with the decisions. While stakeholders 
seemed satisfied with the documented “ideal” process, 
there was dissatisfaction with the actual process, especially 
in relationship to the prioritization of HPV in 2005-2010 
and 2010-2015 in the CMYPs since the actual process did 
not match the HSSIP. Informants’ comments suggest that 
the process of setting and implementing priorities was not 
inclusive, and that there was decreased understanding and 
satisfaction with the process, which resulted in apathy in 
implementing priorities, especially within the districts. While 
stakeholders reported dissatisfaction, no formal complaints 
were reported.
Improved Internal Accountability/Reduced Corruption
Accountability ensures that stakeholders gain confidence in 
the priority setting process and the priority setting institution. 
This confidence will increase stakeholders’ compliance and 
hence facilitate more appropriate use of resources, augmenting 
successful priority setting. Interviews with stakeholders from 
the MoH revealed that although stakeholders were aware 
of the institutions’ existing priority-setting process, there 
was limited transparency and understanding of the actual 
prioritization process in the case of HPV.
Strengthening of the Priority Setting Institution and Impact on 
Institutional Goals and Objectives
In some instances the priority setting institution may be 
independent of the MoH, however, in the case of priority 
setting for vaccines, the MoH is responsible; therefore, the 
parameters related to the priority setting institution are 
assessed under the health system parameters.
Impact on Health Policy and Practice
The priority setting process for the new vaccines did not 
impact health policy. However, the implementation of the 
new vaccines did change health practice since at the time of 
the study, PCV had already been approved for integration into 
the routine vaccination schedule and there were plans to do 
the same for HPV. 
Achievement of Health System Goals 
Successful priority setting should have a positive impact on 
the health system’s achievement of its goals, which include 
improving population health. The effectiveness of PCV and 
HPV vaccines is well documented. While it was not possible 
to objectively assess the impact that the vaccines have had on 
alleviating the disease burden, the population coverage of the 
vaccines can be used an indicator for their potential impact. 
At the time of the study however, HPV had not been rolled 
out in the whole country. 
Improved Financial and Political Accountability
Financial accountability relates to improved tracking 
and reporting on financial allocations, disbursement and 
utilization of financial resources, while political accountability 
relates to the degree of integration of public interests. One 
respondent from the MoH argued that donor influence, 
combined with weak leadership and lack of financial 
accountability on the part of those working in the MoH had 
resulted in a situation in which most of the resources for 
immunization are externally controlled, which impacts timely 
disbursement and implementation.
“…of course we had these other challenges of, what can I say…
corruption or accountability issues. So that has meant that…
they are resources in the hands of partners for whom they 
[the government] doesn’t have control. So I think that limits 
a lot of capacity of the government to implement…people 
in the Ministry could be described as can I say beggars?… 
They are dependent on partners…so…if I give an example 
for immunization, we’ve done a cost evaluation and found 
that most of the resources for immunization are lying outside 
the control of the Program of Immunization. They are either 
with a big entity, National Medical Stores, or they are elusive 
or they are quite ear-marked because they are GAVI funds…
you can only spend on this…” [U_10]. 
The above sentiments were also alluded to in the newspaper 
reviews where delays in district accountabilities for GAVI 
funds for PCV introduction reportedly resulted in delays 
in disbursements of other funds. This led to delays in key 
activities necessary to prepare the health system for PCV 
introduction, particularly health worker training. In turn, 
there were delays in the final roll out of the vaccine, even 
when it had already been launched.32
Increased Investment in the Health Sector and Strengthening of 
the Healthcare System
For the organizations that invest in health systems in LICs, 
increased financial accountability often builds their trust 
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and increases their investments into the health system. 
Furthermore, a successful priority setting process should 
facilitate the strengthening of the priority setting institutions. 
In turn, strong institutions are likely to implement priority 
setting successfully. 
According to the interviewees, the priority setting process 
resulted in increased investment in the health sector 
through the introduction of GAVI funding to support the 
MoH’s delivery of HPV and PCV. The introduction of the 
new vaccines resulted in the training of health personnel, 
strengthening the cold chain and strengthening the disease 
surveillance system. However, these resources and activities 
were directed narrowly towards vaccines. 
GAVI funding to support the MoH’s delivery of HPV and 
PCV increased investment in the health sector. However, 
respondents argued that development assistance partners’ 
influence on the prioritization of new vaccines was 
problematic, because of the hidden costs to national health 
systems associated with the so-called free vaccines. They 
emphasized the considerable work and resources from the 
health system required to introduce new vaccines such as HPV; 
in addition to co-financing, participants discussed additional 
costs, such as the cold chain infrastructure and training for 
health workers required. For example, a participant argued 
that in the past, the influence of development assistance 
partners was less problematic since vaccines were always 
a “good buy.” However, newer vaccines such as HPV are 
more costly. This means that it is important for development 
assistance partners to support countries to make decisions 
based on national preferences and good data.
“…So if you’re measuring progress then what the people 
[development assistance partners] that are being measured 
are going to do is they’re going to run around and try to force 
countries to introduce HPV because then they look good. I 
said you know you’re undermining national decision-making 
by setting a goal in that fashion…So you’re absolutely right 
there are incentives in place to you know push countries to 
make poor decisions…until very recently and one of the 
challenges the vaccines are going to face in the very near 
future is that vaccines were always a good buy... but what’s 
happening and is going to happen in the very near future and 
what GAVI has to be aware of is the new vaccines are not as 
cost effective…” [G_5].
Contextual Factors
Although the MoH had introduced the 2 vaccines, 
participants identified contextual issues that were reported to 
have weakened the institutional capacity of the MoH. These 
negatively impacted the priority setting process for both 
vaccines. 
Participants identified a number of institutional and resource-
related weaknesses in the health system, which impacted 
institutional capacity and continuity, limiting the MoH’s 
ability to implement the stated priorities. Respondents from 
the MoH described how due to apathy and a lack of leadership, 
priorities stated in the HSSIPs failed to be implemented. A 
major issue discussed by participants is the negative influence 
that changes in staffing and leadership at the MoH had on 
the implementation of HSSIP II and the design of HSSIP III. 
During the implementation of the most recent HSSIPs, there 
were multiple changes involving the Ministers of Health and 
their technical arm, the Director General. New appointments 
reportedly resulted in poor transitional processes. This 
inevitably interrupted the implementation of identified 
priorities. Furthermore, respondents reported that some of 
the new leaders seemed anxious to introduce new initiatives, 
while others were not knowledgeable about the previous 
HSSIP. 
Respondents also discussed the negative impact of a lack of 
resources on the institutional capacity for the implementation 
of vaccine priorities. Participants described 2 seemingly 
contradictory issues in relationship to the lack of resources at 
the national level: a lack of resources, and the MoH’s inability 
to use existing resources wisely. While resources may be 
available at the national level, district respondents reported 
that the disbursement of funds from the Ministry to districts 
for the implementation of priorities was often delayed 
considerably, which negatively affected the implementation 
of priorities. With regard to the latter, one district-level 
participant describes:
“…First of all our failure in most cases comes first out of 
failure to have the necessary funds to be disbursed from the 
Ministry, to the district. In most cases we may plan that we 
expect 5 billion from the MoH and then we realize it…has 
been cut…by the Minister of Finance, so that already affects 
the financial disbursement. Secondly, at times the funds 
are not sent in time, and it affects how events are planned” 
[D_1].
MoH respondents also described how limited resources 
negatively influenced districts’ delivery of the new vaccines 
because they impacted key supports for implementation. For 
instance, one respondent explained that a lack of funding 
had resulted in a drop in staffing in the MoH planning 
department, which is responsible for supportive supervision 
for the district. As a result, there was far less interfacing 
with the district. For 2 years, no area teams existed, which 
are the primary structures for communication with the 
districts. A lack of staffing meant that the dissemination of 
the implementation plans for the new vaccines were not well 
actualized at the district level.
Another major challenge discussed by participants is a 
stagnant budget for vaccines. Respondents described how 
the budget for routine vaccines has not grown, however, the 
number and cost of new vaccines such as HPV and PCV is 
expanding, in addition to the population size, number of 
districts and the disease burden, which increases the pressure 
on the national budget. As one participant noted:
“…But overall the budget for the health sector over the last 
few years has actually not grown…actually it has been going 
down and yet we have seen population but also disease 
burden…not just burden but the case mix of diseases has 
been expanding but also …the packages have been expanding 
but not necessarily the resources” [U_18]. 
To ameliorate these issues, global level respondents suggested 
that development assistance partners should align their 
priorities with those of national governments. However, as 
one technical partner argued, while the concept of donor 
harmonization has been promoted, it has not been well 
operationalized; the harmonization of the stakeholders 
involved in vaccine priority setting is negatively impacted by 
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weak institutional capacity in countries such as Uganda:
“…harmonization means that everybody agrees that we 
need to do things differently. Partners should align among 
themselves in the first place and secondly they should align 
with countries’ priority. But it is still a challenge to…to 
operationalize this approach at country level and I think it 
is because you know the system in most of these countries is 
still weak…So each partner will then go, you know, their own 
way because it is just difficult for the national health system 
to coordinate all this. And also the partners want quick 
results and if there isn’t results coming very quickly then they 
will do the things by themselves. So the way I think, what 
will help to…really sort out this is to have strong system and 
institutions in the countries…” [G_6].
Discussion
This paper contributes to the current literature by describing 
and evaluating priority setting for 2 new vaccines in Uganda 
using Kapiriri and Martin’s framework,6 which was developed 
to evaluate priority setting in these contexts. To our 
knowledge, this is one of the first case studies to examine the 
influence of the global, national and sub-national levels on 
priority setting for new vaccines. While this study draws on 
the Ugandan context, the national and local decision-making 
dynamics in the Ugandan public health system, as well as the 
economic and political power differences between its MoH 
and development assistance partners, are similar to those 
in other LICs, and thus, provide a basis for generalizations 
beyond the Ugandan context. 
The parameters of successful priority setting are summarized 
in Table 5. First, the parameters that could be assessed and 
whether or not the priority setting processes satisfied these 
quality indicators is discussed. Lastly, the parameters that 
could not be assessed and the implications of these findings 
are discussed (see Table 4).
Based on the parameters in Kapiriri and Martin’s framework,6 
the process for prioritizing both vaccines was successful in 
a few ways. First, although no framework was used in the 
priority setting process for either vaccine, our data suggest that 
the decisions to introduce both HPV and PCV were based on 
considerations of evidence; while HPV used evidence from a 
pilot project in 2 districts, PCV used evidence from sentinel 
surveillance reports and community studies. In addition, both 
vaccines were prioritized based on explicit relevant criteria: 
cost-effectiveness for PCV and burden and disease and equity 
for HPV. While stakeholders from the MoH were generally 
satisfied with the decision to introduce PCV, several expressed 
dissatisfaction with the prioritization of HPV in 2005-2010 
and 2010-2015 in the CMYPs since the actual process did not 
match the HSSIP. Stakeholders’ understanding of the priority 
setting process for PCV was better as compared to HPV since 
PCV was one of the original priorities set by the MoH, while 
HPV was not. In the case of HPV, the allocation of resources 
toward the vaccine did not successfully follow the original 
plan set by the MoH. 
According to some respondents, unacceptable criteria such 
as external monies and influence affected priority setting in 
2005-2010 and 2010-2015. The prioritization of HPV was 
based more on the influence of donors and industry and 
political sentiment than technical priorities; this contributed to 
stakeholders’ dissatisfaction with the priority setting process. 
Banura and colleagues16 describe how both formulations of 
HPV vaccines were introduced to Uganda through donations 
to the MoH. First, GlaxoSmithKline donated 50 000 doses 
of Cervarix to vaccinate girls in Nakasongola and Ibanda 
districts. Then, Merk and Co. donated 1600 doses of Gardasil 
to vaccinate 500 HIV-positive girls.13
A lack of participation of key stakeholders contributed to 
dissatisfaction with the priority setting process for both HPV 
and PCV. There was a sense that because of a lack of leadership 
in the MoH, compliance with the priority setting process had 
decreased and the process had become less consultative, in 
which the participation of key actors such as MoH staff and 
the district officers had declined. This was in part explained by 
the changes in top leadership in the MoH and a reduction in 
development assistance partners’ adherence to a consultative 
priority setting process. However, despite the dissatisfaction 
with the priority setting process expressed by many of our 
respondents in interviews, no dissentions were formally 
recorded in reports. In some of the newspaper reports, the 
public reacted negatively to the new vaccine (HPV) but 
no explicit complaints or revisions to the decisions were 
documented or mentioned by our respondents. This could be 
explained by the lack of explicit mechanisms for appealing the 
decisions. 
In terms of the achievement of health system objectives, 
indicators such as the percent reduction in disability-adjusted 
life years (DALYs) could not be measured; however at the time 
of the data collection, the implementation of both vaccines 
was contributing to the health system’s goals of reducing 
morbidity. Arguably, the implementation of PCV, which was 
scaled up completely across the country, contributed more to 
this goal than HPV, which remained at the pilot phase at the 
time of the study. In terms of increasing investment into and 
strengthening of the health sector, the priority setting process 
may have met this parameter; this is because the introduction 
of the new vaccines involved substantial investment into the 
health sector and supported other health sector activities such 
as disease surveillance and capacity building. However, this 
was specific to EPI.
While GAVI expects and facilitates improved financial 
accountability at the national level,15 this did not seem 
to trickle down to the districts where delays in district 
accountabilities for PCV affected vaccine implementation; 
although this problem was later rectified. 
Consistent with the literature, contextual factors impacted 
the parameters of successful priority setting.34 Some of the 
factors, such as strong political commitment to vaccines 
facilitated the introduction of the new vaccines. However, 
most of the contextual factors negatively impacted priority 
setting. For example, the political decisions to change the top 
management, the influence of donor and industry priorities, 
and the economic context, which led to a lack of expansion 
of the budget for the health sector and subsequently resulted 
in inadequate staff for implementation at the district level, all 
had a negative influence on priority setting.
A few parameters could not be assessed. The priority setting 
process should increase public awareness of priority setting, 
involve the increased input of the public and reflect public 
values, and facilitate public confidence and acceptance of 
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decisions. The assessment of these criteria was mixed. It was 
not possible to assess increased public awareness of priority 
setting and increased public confidence in and acceptance of 
decisions since these parameters necessitated interviewing 
members of the public. It was also not possible to assess 
whether the priority setting process reflected public values, 
since the documents reviewed do not show the exact role 
played by the public in the priority setting process. Finally it 
was also not possible to evaluate the efficiency of the priority 
setting process and decreased resource wastage, parameters 
that require real-time assessment.
Conclusion
Based on the evaluation framework, there are several areas 
where concerted efforts are necessary if priority setting for new 
vaccines is to be deemed successful. First, the prioritization 
of new vaccines should be based on explicit frameworks. The 
lack of clarity as to why and how HPV was prioritized over 
other vaccines that had been identified through a national 
level process calls for commitment to transparency with 
regards to how new vaccines get onto the political agenda. 
HSSIPs should be used as the basis for implementing the 
documented new vaccine priorities. 
There is also a need for enforcement mechanisms to ensure 
that vaccines identified as a priority in the initial HSSIP 
planning process are not overtaken by vaccines that are 
not considered to be a top priority. This requires the direct 
involvement of key stakeholders such as district officers in 
determining national level priorities. The process should also 
require public consultations and involvement. This would 
call for raising public awareness about the priority setting 
process and the rationale behind the decisions. Monitoring 
implementation of the new vaccines should also involve 
monitoring the public response to the set priorities and their 
implementation. The existing power imbalances between 
sub-national governments, national governments and 
their development assistance partners need to be mitigated 
by strengthening institutional capacity and leadership; 
this is essential to ensure that priorities are identified and 
implemented through an inclusive, transparent, and efficient 
process. 
To a great degree, Kapiriri and Martin’s framework and sources 
of information6 provided viable guidance for evaluating the 
degree to which the priority setting processes for identifying 
new vaccines worked in Uganda. The results re-emphasize the 
need for evaluation to be built in the priority setting process 
a priori, and that information on priority setting is gathered 
throughout the implementation cycle as opposed to the 
traditional ex-ante evaluations.5 
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